$6.17
5.80% yesterday
Nasdaq, Nov 15, 10:01 pm CET
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Terns Pharmaceuticals Inc Stock price

$6.17
-1.43 18.82% 1M
+0.18 3.01% 6M
-0.32 4.93% YTD
+2.32 60.26% 1Y
-2.32 27.33% 3Y
-10.83 63.71% 5Y
-10.83 63.71% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.38 5.80%
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Key metrics

Market capitalization $553.06m
Enterprise Value $181.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-99.98m
Free Cash Flow (TTM) Free Cash Flow $-74.91m
Cash position $372.78m
EPS (TTM) EPS $-1.18
P/E forward negative
Short interest 5.91%
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Terns Pharmaceuticals Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
78%
Hold
22%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.90 0.90
22% 22%
-
-0.90 -0.90
22% 22%
-
- Selling and Administrative Expenses 29 29
21% 21%
-
- Research and Development Expense 70 70
23% 23%
-
-99 -99
5% 5%
-
- Depreciation and Amortization 0.90 0.90
22% 22%
-
EBIT (Operating Income) EBIT -100 -100
5% 5%
-
Net Profit -88 -88
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Negative
Market Watch
about 10 hours ago
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.
Neutral
GlobeNewsWire
about one month ago
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee unde...
Positive
Seeking Alpha
about 2 months ago
Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected i...
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 66
Founded 2017
Website www.ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today